Market Place
Sourcing Support
Dermata Reports Q3 2024 Financial Update
13 Nov 2024 //
ACCESSWIRE
Dermata To Participate In 2024 Maxim Healthcare Virtual Summit
08 Oct 2024 //
ACCESSWIRE
Dermata Therapeutics Closes $3.5 Million Private Placement Priced At-The-Market
17 Sep 2024 //
ACCESSWIRE
Dermata Therapeutics Announces $3.5 Million Private Placement
16 Sep 2024 //
ACCESSWIRE
Dermata To Participate In H.C. Wainwright Conference
05 Sep 2024 //
ACCESSWIRE
Dermata Therapeutics Reports Q2 2024 Results And Corporate Update
07 Aug 2024 //
ACCESSWIRE
Dermata Announces $2.66M Warrant Exercise Priced At-Market
17 May 2024 //
ACCESSWIRE
Dermata Provides Corporate Update, Reports Q1 2024 Financials
15 May 2024 //
ACCESSWIRE
Dermata to Present at the Emerging Growth Conference on April 3, 2024
27 Mar 2024 //
ACCESSWIRE
Dermata Expands Patent Portfolio with Issuance of Patent for DMT410
04 Jan 2024 //
ACCESSWIRE
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program
16 Nov 2023 //
PRESS RELEASE
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds
16 Nov 2023 //
ACCESSWIRE
Dermata Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
ACCESSWIRE
Dermata Announces +VE Feedback from FDA the DMT310 Ph3 Clinical DeveP Program
27 Jun 2023 //
ACCESSWIRE
Dermata Announces Submission of DMT310 End of Phase 2 Meeting Package
20 Apr 2023 //
PRESS RELEASE
Dermata Therapeutics Announces Closing of $5.0 Million Public Offering
20 Mar 2023 //
ACCESSWIRE
Why The Dermata Therapeutics (DRMA) Stock Surged 104.5%
30 Dec 2022 //
PULSE2
Dermata Announces Topline Results DMT310 Ph2 Trial forModerate-to-Severe Rosacea
06 Dec 2022 //
PRESS RELEASE
Dermata`s mid-stage rosacea study sees far-from-rosy results
05 Dec 2022 //
FIERCEBIOTECH
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement
25 Apr 2022 //
BARRONS
Dermata Therapeutics Announces $5.0 Million Private Placement Priced
21 Apr 2022 //
YAHOO
Dermata Therapeutics Reports Full Year 2021 Financial Results
28 Mar 2022 //
PRESS RELEASE
Dermata Tx to Participate in the 2022 Maxim Group Virtual Growth Conference
24 Mar 2022 //
PRESS RELEASE
Dermata Therapeutics, Inc.has submitted requests to (the “FDA”) for the waive
07 Feb 2022 //
PRESS RELEASE
Dermata Begins Enrollment in Phase 2 Trial of DMT310 for Rosacea
17 Nov 2021 //
BIOSPACE
Dermata reports Phase I data of DMT310 to treat psoriasis
19 Oct 2021 //
CLINICALTRIALSARENA
Dermata Reports Second Quarter 2021 Financial Results
27 Sep 2021 //
YAHOO
Dermata to Present Results from DMT410 Phase 1b Proof of Concept Aesthetic Study
21 Sep 2021 //
ACCESSWIRE
Dermata Therapeutics Announces Closing of Upsized $18.0M Initial Public Offering
17 Aug 2021 //
FIRSTWORDPHARMA
Dermata Therapeutics Announces Closing of Upsized $18.0 Million IPO
17 Aug 2021 //
BIO SPACE
Dermatology biotech Dermata Therapeutics sets terms for $15 million IPO
05 Jul 2021 //
RENAISSANCECAPITAL
Dermatology biotech Dermata Therapeutics files for an $18 million IPO
11 Jun 2021 //
RENAISSANCE CAPITAL
Dermata Therapeutics Announces Initiation of a Phase 1b Trial of DMT310
30 Mar 2021 //
PRNEWSWIRE
Dermata Presents Positive Data From its Phase 2b Clinical Study of DMT310
21 Jan 2021 //
PRNEWSWIRE
